Kodiak's eye drug falls short of Eylea in trial, shares sink – Reuters

Feb 23 (Reuters) – Kodiak Sciences Inc's (KOD.O) eye drug failed to match Regeneron Pharmaceuticals' (REGN.O) Eylea in improving the vision of patients in a study, sending its shares tumbling nearly 80% on Wednesday.
The mid-to-late-stage trial was testing the lead experimental eye drug in 559 patients with wet macular degeneration, a chronic eye disorder that causes blurred vision or blind spots.
While the results from the study showed the drug was safe, overall it did not improve vision as effectively as Eylea, prompting Kodiak's management to blame undertreatment for the drug's failure as the trial protocol did not allow more frequent dosing.
The company is now awaiting data from another ongoing trial early next year, said Chief Executive Victor Perlroth on a call with analysts. That study uses monthly dosing of the drug, instead of the three-to-five month interval used in the current trial.
Analysts, however, are skeptical about the new study, citing safety concerns around the drug's frequent dosing, compared with once every two months for Eylea.
The monthly study will be critical for inflammation and safety, as 3.2% of patients on Kodiak's drug had inflammation despite not being dosed frequently, compared with none for Eylea, Jefferies analyst Michael Yee wrote in a note.
For Regeneron, failure of Kodiak's drug, KSI-301, removes a key overhang on the stock as Eylea is its top-selling treatment, generating nearly $6 billion in sales last year. Shares of Kodiak hit a 2-1/2 year low of $10.17 in morning trade, while those of Regeneron rose nearly 1%.
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved


Add a Comment

Your email address will not be published. Required fields are marked *